Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study

Authors

  • Federica Repetto Department of Medical Sciences, Section of Dermatology, University of Turin, Via Cherasco 23, 10126, Turin, Italy
  • Gabriele Roccuzzo Department of Medical Sciences, Section of Dermatology, University of Turin, Via Cherasco 23, 10126, Turin, Italy
  • Lorenza Burzi Department of Medical Sciences, Section of Dermatology, University of Turin, Via Cherasco 23, 10126, Turin, Italy
  • Luca Mastorino Department of Medical Sciences, Section of Dermatology, University of Turin, Via Cherasco 23, 10126, Turin, Italy
  • Paolo Dapavo Department of Medical Sciences, Section of Dermatology, University of Turin, Via Cherasco 23, 10126, Turin, Italy
  • Pietro Quaglino Department of Medical Sciences, Section of Dermatology, University of Turin, Via Cherasco 23, 10126, Turin, Italy
  • Simone Ribero Department of Medical Sciences, Section of Dermatology, University of Turin, Via Cherasco 23, 10126, Turin, Italy

DOI:

https://doi.org/10.2340/actadv.v103.5278

Keywords:

Hidradenitis Suppurativa, Adalimumab, Risankizumab, Guselkumab, Secukinumab

Abstract

Abstract is missing (Short communication)

Downloads

Download data is not yet available.

References

Morita A, Takahashi H, Ozawa K, Imafuku S, Takekuni N, Takahashi K, et al. Long-term analysis of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa: open-label phase 3 results. J Dermatol 2021; 48: 3-13.

https://doi.org/10.1111/1346-8138.15605 DOI: https://doi.org/10.1111/1346-8138.15605

Roccuzzo G, Rozzo G, Burzi L, Repetto F, Dapavo P, Ribero S, Quaglino P. Switching from adalimumab originator to biosimilars in hidradenitis suppurativa: what's beyond cost-effectiveness? Dermatol Ther 2022; 35: e15803.

https://doi.org/10.1111/dth.15803 DOI: https://doi.org/10.1111/dth.15803

Markota Čagalj A, Marinović B, Bukvić Mokos Z. New and emerging targeted therapies for hidradenitis suppurativa. Int J Mol Sci 2022; 23: 3753.

https://doi.org/10.3390/ijms23073753 DOI: https://doi.org/10.3390/ijms23073753

Repetto F, Burzi L, Ribero S, Quaglino P, Dapavo P. Efficacy and safety of risankizumab in hidradenitis suppurativa: a case series. Acta Derm Venereol 2022; 102: adv00780.

https://doi.org/10.2340/actadv.v102.2926 DOI: https://doi.org/10.2340/actadv.v102.2926

Melgosa Ramos FJ, García Ruiz R, Mateu Puchades A, Alfageme Roldán F. Guselkumab effectiveness, and posology in patients with moderate to severe hidradenitis suppurativa: a retrospective bicentric experience. Dermatol Ther 2022; 35: e15558.

https://doi.org/10.1111/dth.15558 DOI: https://doi.org/10.1111/dth.15558

Burzi L, Repetto F, Ramondetta A, Rozzo G, Licciardello M, Ribero S, Quaglino P, Dapavo P. Guselkumab in the treatment of severe hidradenitis suppurativa, a promising role? Dermatol Ther 2021; 34: e14930.

https://doi.org/10.1111/dth.14930 DOI: https://doi.org/10.1111/dth.14930

Ribero S, Ramondetta A, Fabbrocini G, Bettoli V, Potenza C, Chiricozzi A, et al. Effectiveness of Secukinumab in the treatment of moderate-severe hidradenitis suppurativa: results from an Italian multicentric retrospective study in a real-life setting. J Eur Acad Dermatol Venereol 2021; 35: e441-e442.

https://doi.org/10.1111/jdv.17178 DOI: https://doi.org/10.1111/jdv.17178

Revuz JE, Jemec GB. Diagnosing hidradenitis suppurativa. Dermatol Clin 2016; 34: 1-5.

https://doi.org/10.1016/j.det.2015.08.009 DOI: https://doi.org/10.1016/j.det.2015.08.009

Zouboulis CC, Tzellos T, Kyrgidis A, Jemec GBE, Bechara FG, Giamarellos-Bourboulis EJ, et al. Development and validation of the International Hidradenitis Suppurativa Severity Score System (IHS4), a novel dynamic scoring system to assess HS severity. Br J Dermatol 2017; 177: 1401-1409.

https://doi.org/10.1111/bjd.15748 DOI: https://doi.org/10.1111/bjd.15748

Cazzaniga S, Pezzolo E, Bettoli V, et al. Characterization of hidradenitis suppurativa phenotypes: a multidimensional latent class analysis of the National Italian Registry IRHIS. J Invest Dermatol 2021; 141: 1236-1242.e1.

https://doi.org/10.1016/j.jid.2020.08.032 DOI: https://doi.org/10.1016/j.jid.2020.08.032

Finlay AY, Khan GK. Dermatology Life Quality Index (DLQI) - a simple practical measure for routine clinical use. Clin Exp Dermatol 1994; 19: 210-216.

https://doi.org/10.1111/j.1365-2230.1994.tb01167.x DOI: https://doi.org/10.1111/j.1365-2230.1994.tb01167.x

Downloads

Published

2023-04-19

How to Cite

Repetto, F., Roccuzzo, G., Burzi, L., Mastorino, L., Dapavo, P., Quaglino, P., & Ribero, S. (2023). Drug Survival of Anti Interleukin-17 and Interleukin -23 Agents after Adalimumab Failure in Hidradenitis Suppurativa: A Pilot Study. Acta Dermato-Venereologica, 103, adv5278. https://doi.org/10.2340/actadv.v103.5278

Issue

Vol. 103 (2023)

Section

Short Communication

Categories

License

Copyright (c) 2023 Federica Repetto, Gabriele Roccuzzo, Lorenza Burzi, Luca Mastorino, Paolo Dapavo, Pietro Quaglino, Simone Ribero

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.

Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.

Crossref
Scopus
Google Scholar
Europe PMC